MedTrace Logo

Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

NCT00602680 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2009-07-20

No results posted yet for this study

Summary

The primary objective of the study is to assess the effect of 3 doses of SSR180711C on cognitive performance in patients with mild Alzheimer's Disease (AD). Other objectives are to assess the safety/tolerability of SSR180711C in patients with mild AD.

Conditions

Interventions

DRUG

SSR180711C

duration of treatment: 4 weeks

DRUG

donepezil

duration of treatment: 4 weeks

DRUG

placebo

duration of treatment: 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Bruno DUBOIS, MD · Scientific Advisory Committee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00602680 on ClinicalTrials.gov